Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2018 December;66(6) > Minerva Cardioangiologica 2018 December;66(6):718-28

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

REVIEW  TRICUSPID VALVE INTERVENTIONS 

Minerva Cardioangiologica 2018 December;66(6):718-28

DOI: 10.23736/S0026-4725.18.04657-1

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Transcatheter therapies for tricuspid regurgitation: coaptation augmentation devices

Edwin C. HO, Neil P. FAM

Division of Cardiology, St. Michael’s Hospital, Toronto, ON, Canada



Advancements in transcatheter technology has increased the number of therapeutic options for patients with tricuspid regurgitation. One category of repair devices attempts to augment leaflet coaptation by either leaflet plication or by functioning as a space occupying device. These include the MitraClip (Abbott, Santa Clara, CA, USA), PASCAL (Edwards Lifesciences, Irvine, CA, USA) and FORMA (Edwards Lifesciences, Irvine, CA, USA) devices. All three have been successfully implanted with promising short-term echocardiographic and clinical outcomes. Improvements in patient selection, device design and procedural technique will lead to more effective tricuspid regurgitation reduction. Further research to assess efficacy, safety and durability of these devices is needed, along with determination of long-term clinical outcomes.


KEY WORDS: Tricuspid valve insufficiency - Heart valve diseases - Safety - Prostheses and implants

inizio pagina